NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clementia Pharmaceuticals Inc. CMTA, MyoKardia, Inc. MYOK, Landec Corporation LNDC, Sapiens International Corporation N.V. SPNS, AppFolio, Inc. APPF, and China Biologic Products, Inc. CBPO, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
CMTA DOWNLOAD: http://Fundamental-Markets.com/register/?so=CMTA
MYOK DOWNLOAD: http://Fundamental-Markets.com/register/?so=MYOK
LNDC DOWNLOAD: http://Fundamental-Markets.com/register/?so=LNDC
SPNS DOWNLOAD: http://Fundamental-Markets.com/register/?so=SPNS
APPF DOWNLOAD: http://Fundamental-Markets.com/register/?so=APPF
CBPO DOWNLOAD: http://Fundamental-Markets.com/register/?so=CBPO
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Clementia Pharmaceuticals Inc. CMTA, MyoKardia, Inc. MYOK, Landec Corporation LNDC, Sapiens International Corporation N.V. SPNS, AppFolio, Inc. APPF, and China Biologic Products, Inc. CBPO on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 14th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
CLEMENTIA PHARMACEUTICALS INC. (CMTA) REPORT OVERVIEW
Clementia Pharmaceuticals' Recent Financial Performance
Clementia Pharmaceuticals is expected to report earnings on May 23rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The estimated EPS forecast for the next fiscal year is -$1.40 and is expected to report on February 27th, 2019.
To read the full Clementia Pharmaceuticals Inc. (CMTA) report, download it here: http://Fundamental-Markets.com/register/?so=CMTA
-----------------------------------------
MYOKARDIA, INC. (MYOK) REPORT OVERVIEW
MyoKardia's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, MyoKardia reported revenue of $5.63MM vs $28.55MM (down 80.30%) and basic earnings per share -$0.20 vs $0.56. For the twelve months ended December 31st, 2017 vs December 31st, 2016, MyoKardia reported revenue of $22.50MM vs $39.20MM (down 42.60%) and basic earnings per share -$1.40 vs -$0.48. MyoKardia is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.37. The estimated EPS forecast for the next fiscal year is -$2.37 and is expected to report on March 14th, 2019.
To read the full MyoKardia, Inc. (MYOK) report, download it here: http://Fundamental-Markets.com/register/?so=MYOK
-----------------------------------------
LANDEC CORPORATION (LNDC) REPORT OVERVIEW
Landec's Recent Financial Performance
For the three months ended November 30th, 2017 vs November 30th, 2016, Landec reported revenue of $136.46MM vs $135.87MM (up 0.44%) and basic earnings per share $0.02 vs $0.05 (down 60.00%). For the twelve months ended May 31st, 2017 vs May 31st, 2016, Landec reported revenue of $532.26MM vs $541.10MM (down 1.63%) and basic earnings per share $0.39 vs -$0.43. Landec is expected to report earnings on April 3rd, 2018. The report will be for the fiscal period ending February 28th, 2018. The reported EPS for the same quarter last year was $0.13. The estimated EPS forecast for the next fiscal year is $0.70 and is expected to report on July 24th, 2018.
To read the full Landec Corporation (LNDC) report, download it here: http://Fundamental-Markets.com/register/?so=LNDC
-----------------------------------------
SAPIENS INTERNATIONAL CORPORATION N.V. (SPNS) REPORT OVERVIEW
Sapiens International Corporation N.V's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Sapiens International Corporation N.V reported revenue of $72.01MM vs $56.48MM (up 27.50%) and basic earnings per share $0.06 vs $0.11 (down 45.45%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Sapiens International Corporation N.V reported revenue of $216.19MM vs $185.64MM (up 16.46%) and basic earnings per share $0.40 vs $0.42 (down 4.76%). Sapiens International Corporation N.V is expected to report earnings on May 21st, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.01.
To read the full Sapiens International Corporation N.V. (SPNS) report, download it here: http://Fundamental-Markets.com/register/?so=SPNS
-----------------------------------------
APPFOLIO, INC. (APPF) REPORT OVERVIEW
AppFolio's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, AppFolio reported revenue of $37.90MM vs $28.01MM (up 35.30%) and basic earnings per share $0.08 vs -$0.04. For the twelve months ended December 31st, 2017 vs December 31st, 2016, AppFolio reported revenue of $143.80MM vs $105.59MM (up 36.20%) and basic earnings per share $0.29 vs -$0.25. AppFolio is expected to report earnings on May 4th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.02. The estimated EPS forecast for the next fiscal year is $0.56 and is expected to report on February 25th, 2019.
To read the full AppFolio, Inc. (APPF) report, download it here: http://Fundamental-Markets.com/register/?so=APPF
-----------------------------------------
CHINA BIOLOGIC PRODUCTS, INC. (CBPO) REPORT OVERVIEW
China Biologic Products' Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, China Biologic Products reported revenue of $90.11MM vs $77.63MM (up 16.08%) and basic earnings per share -$0.88 vs $0.69. For the twelve months ended December 31st, 2017 vs December 31st, 2016, China Biologic Products reported revenue of $370.41MM vs $341.17MM (up 8.57%) and basic earnings per share $2.40 vs $3.79 (down 36.68%). China Biologic Products is expected to report earnings on May 2nd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $1.32. The estimated EPS forecast for the next fiscal year is $5.88 and is expected to report on February 27th, 2019.
To read the full China Biologic Products, Inc. (CBPO) report, download it here: http://Fundamental-Markets.com/register/?so=CBPO
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
